Nuritas Gets Money to Expand the Peptide Discovery

Nuritas, a Dublin-based biotech firm that employs proprietary AI to find plant-based bioactive peptides, has raised $45 million (about €39 million) in a Series B round of funding. To date, the company has raised $75 million (about €65 million) in investment. Cleveland Avenue led the financing, including the Wheatsheaf Group of Grosvenor, the European Circular Bioeconomy Fund (ECBF), Singapore-based Vertex Holdings, Nutresa Ventures/Veronorte, Cultivian Sandbox Ventures, and VisVires New Protein.

Bono and The Edge of U2, Salesforce CEO Marc Benioff, and entrepreneur Ali Partovi are among the early backers of Nuritas. Cleveland Avenue is a venture capital firm based in Chicago that invests in food and beverage brands and digital firms that disrupt huge and expanding markets.

The new money will help the company grow globally and work on peptides, smaller proteins with additional highly specialized benefits. Randall Lewis, managing director of Cleveland Avenue, LLC, and Stephan Dolezalek, executive director of Grosvenor’s Wheatsheaf Group, will join Nuritas‘ Board of Directors as part of the financing round.

The Irish firm has positioned itself as the world’s most comprehensive peptide database. By replacing undesired components and compounds with more sustainable and natural ones, the company hopes to manage and improve human health and contribute to a better food system. Nuritas, founded by Nora Khaldi, analyses billions of hidden peptides in plants and natural food sources and their impact on health regions, biochemical pathways, and receptors using a proprietary AI and genomics platform called N (Nuritas Peptide Finder).